These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27127393)

  • 61. The management of menopausal symptoms in breast cancer survivors: case-based approach.
    Lammerink EA; de Bock GH; Schröder CP; Mourits MJ
    Maturitas; 2012 Nov; 73(3):265-8. PubMed ID: 22883373
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
    Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
    BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Connectome analysis of brain functional network alterations in breast cancer survivors with and without chemotherapy.
    Chen VC; Lin KY; Tsai YH; Weng JC
    PLoS One; 2020; 15(5):e0232548. PubMed ID: 32365133
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Overview of long term care of breast cancer survivors.
    Brennan ME; Houssami N
    Maturitas; 2011 Jun; 69(2):106-12. PubMed ID: 21489727
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy.
    Peppone LJ; Janelsins MC; Kamen C; Mohile SG; Sprod LK; Gewandter JS; Kirshner JJ; Gaur R; Ruzich J; Esparaz BT; Mustian KM
    Breast Cancer Res Treat; 2015 Apr; 150(3):597-604. PubMed ID: 25814054
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hormonal breast cancer agents: implications for the primary care provider.
    Lyon DE; Roux G; Voll S
    J Am Acad Nurse Pract; 2006 Nov; 18(11):518-23. PubMed ID: 17064329
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis.
    Bell RJ; Schwarz M; Fradkin P; Robinson PJ; Davis SR
    Menopause; 2013 Jul; 20(7):721-6. PubMed ID: 23793165
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment.
    Collins B; Mackenzie J; Stewart A; Bielajew C; Verma S
    Psychooncology; 2009 Feb; 18(2):134-43. PubMed ID: 18551510
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Age-related patterns of care: evidence against ageism in the treatment of early-stage breast cancer.
    Guadagnoli E; Shapiro C; Gurwitz JH; Silliman RA; Weeks JC; Borbas C; Soumerai SB
    J Clin Oncol; 1997 Jun; 15(6):2338-44. PubMed ID: 9196148
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research.
    Perez-Gracia JL; Carrasco EM
    Gynecol Oncol; 2002 Feb; 84(2):201-9. PubMed ID: 11812075
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Endothelial Dysfunction in Childhood Cancer Survivors: A Narrative Review.
    Crocco M; d'Annunzio G; La Valle A; Piccolo G; Chiarenza DS; Bigatti C; Molteni M; Milanaccio C; Garrè ML; Di Iorgi N; Maghnie M
    Life (Basel); 2021 Dec; 12(1):. PubMed ID: 35054438
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Metabolic Syndrome in Breast Cancer Patients: An Observational Study.
    Khare S; Irrinki S; Sakaray YR; Bal A; Singh T; Singh G
    Breast Cancer (Auckl); 2021; 15():11782234211026788. PubMed ID: 34629874
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prevalence of metabolic syndrome among breast cancer survivors in East Coast of Peninsular Malaysia.
    Shahril MR; Amirfaiz S; Lua PL; Nurnazahiah A; Zakarai NS; Kow VL; Ahmad A; Sulaiman S
    BMC Public Health; 2021 Jan; 21(1):238. PubMed ID: 33509143
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Metabolic syndrome induced by anticancer treatment in childhood cancer survivors.
    Chueh HW; Yoo JH
    Ann Pediatr Endocrinol Metab; 2017 Jun; 22(2):82-89. PubMed ID: 28690985
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Incidence of metabolic syndrome in breast cancer survivors on adjuvant hormonal therapy.
    Kate A; Kadambari D
    J Pharmacol Pharmacother; 2016; 7(1):28-30. PubMed ID: 27127393
    [No Abstract]   [Full Text] [Related]  

  • 76. Understanding Breast Cancer Survivors' Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence.
    Hurtado-de-Mendoza A; Jensen RE; Jennings Y; Sheppard VB
    J Cancer Educ; 2018 Apr; 33(2):436-439. PubMed ID: 28205022
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Symptoms of hormonal therapy and social support: Is there a connection? Comparison of symptom severity, symptom interference and social support among breast cancer patients receiving and not receiving adjuvant hormonal treatment.
    Ochayon L; Tunin R; Yoselis A; Kadmon I
    Eur J Oncol Nurs; 2015 Jun; 19(3):260-7. PubMed ID: 25529935
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
    Bell R; Lewis J
    Curr Med Res Opin; 2007 May; 23(5):1045-51. PubMed ID: 17519070
    [TBL] [Abstract][Full Text] [Related]  

  • 79. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Skeletal health in breast cancer survivors.
    Bruyère O; Bergmann P; Cavalier E; Gielen E; Goemaere S; Kaufman JM; Rozenberg S; Body JJ
    Maturitas; 2017 Nov; 105():78-82. PubMed ID: 28838807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.